Redmile Group ORKA Position
Exited7-Fund ConvergenceRedmile Group exited their position in Oruka Therapeutics, Inc. (ORKA) in Q2 2025, after holding the stock for 4 quarters.
The position was first reported in Q3 2024 and has been tracked across 4 quarterly 13F filings.
ORKA is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ORKA-001 Induction Dose in 14 days (Apr 30, 2026), making the timing of Redmile's position particularly relevant.
Short interest stands at 10.3% of float with 9.1 days to cover, indicating significant bearish positioning against the stock.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Full company profile →Short Interest
10.3%
9.1 days to cover
Redmile Group ORKA Position History
Frequently Asked Questions
Does Redmile Group own ORKA?
No. Redmile Group exited their position in Oruka Therapeutics, Inc. (ORKA) in Q2 2025. They previously held the stock for 4 quarters.
How many hedge funds own ORKA?
7 specialist biotech hedge funds currently hold ORKA, including Deep Track Capital, RTW Investments, Commodore Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Redmile Group first buy ORKA?
Redmile Group's position in ORKA was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Redmile Group's ORKA position increasing or decreasing?
Redmile Group completely exited their ORKA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ORKACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Redmile GroupPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →